Ligand Pharmaceuticals Incorporated /
Orchestra BioMed Holdings, Inc.
Ligand Pharmaceuticals to purchase revenue rights from Orchestra BioMed
Source for the buyer and target: Orchestra BioMed Holdings, Inc.
For the buyer and target.
“On July 31, 2025, Orchestra BioMed Holdings, Inc. (the “ Company ”) entered into a revenue participation right purchase and sale agreement (the “ Revenue Purchase and Sale Agreement ”) with Ligand Pharmaceuticals Incorporated (the “ Purchaser ”).”
Published 31 Jul 2025
Open the sourceWhat happened
Ligand Pharmaceuticals Incorporated entered into an agreement with Orchestra BioMed Holdings, Inc. for a revenue participation right purchase. The agreement covers revenue tied to the company’s BACKBEAT therapy and Virtue Sirolimus AngioInfusion Balloon. [01]
The investment amount is $35.0 million, less certain reimbursable expenses. The filing says closing is subject to certain conditions. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Ligand Pharmaceuticals to purchase revenue rights from Orchestra BioMed
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly